AbbeyMoor updates Spanner stent design
This article was originally published in The Gray Sheet
Executive Summary
FDA grants supplemental PMA approval for design changes to the prostatic stent aimed at increasing flexibility and patient comfort, AbbeyMoor Medical announces July 6. Spanner, a temporary stent that aids men experiencing difficulty urinating due to prostatic obstruction, received PMA approval in 2006. The device is marketed as an alternative to indwelling catheterization, intermittent catheterization or the use of a suprapubic tube
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.